Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Mirati Therapeutics Is Jumping Today

By Cory Renauer – Updated Jun 5, 2019 at 2:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It looks like a target considered undruggable is actually within reach.

What happened

Shares of Mirati Therapeutics (MRTX 3.98%), a clinical-stage biopharmaceutical company with an oncology focus, are on the rise following a presentation from Amgen (AMGN -0.48%). Mirati investors were happy to see the industry giant report encouraging data from a new drug candidate similar to one that Mirati is developing, and have pushed the stock up 36.2% as of 11:57 a.m. EDT on Monday.

So what 

After Mirati's lead candidate, sitravatinib, disappointed investors late last year, the company is depending heavily on a candidate licensed from Array Biopharma (ARRY) called MRTX849. This is a small-molecule drug that stops mutated KRas proteins from signaling for rapid growth and cell division.

Happy investor surrounded by falling banknotes.

Image source: Getty Images.

Investigators have been trying to inhibit out-of-control KRas proteins from promoting tumor growth for decades without success because the protein presents a target that's particularly difficult to reach. Another drug aimed at reducing KRas protein production from AstraZeneca and Ionis Pharmaceuticals failed its first human proof-of-concept study recently, and investors were worried that the whole KRas class was doomed.

Mirati's stock is on the rise today because Amgen's KRas inhibitor, called AMG 510, performed well enough to suggest Mirati is on the right track as well. AMG 510 helped shrink tumors for five out of 10 lung cancer patients. Of the 18 patients with colorectal cancer, 13 achieved stable disease. It's important to point out that these were relapsed patients who had already been through a wringer involving at least two rounds of standard treatment.

Now what

Mirati doesn't have any past successes to boast about, but the company that discovered MRTX849 sure does. Array Biopharma has produced more than one successful cancer treatment and recently proved it can design small-molecule drugs that can inhibit difficult targets with high specificity. 

Earlier this year, Eli Lilly (LLY -1.70%) bought Loxo Oncology for $8 billion after another small-molecule, Loxo, licensed from Array performed better than expectations. That doesn't necessarily mean that MRTX849 is destined to succeed as well, but investors will make this association until it's disproved by trial results.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Ionis Pharmaceuticals. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.